

# **Toxoplasmosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update**

<https://marketpublishers.com/r/T2510AD7A8F8EN.html>

Date: December 2022

Pages: 44

Price: US\$ 2,000.00 (Single User License)

ID: T2510AD7A8F8EN

## **Abstracts**

Toxoplasmosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

### **SUMMARY**

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Toxoplasmosis - Drugs In Development, 2022, provides an overview of the Toxoplasmosis (Infectious Disease) pipeline landscape.

Toxoplasmosis is a disease that results from infection with the *Toxoplasma gondii* parasite. Symptoms include body aches, swollen lymph nodes, headache, fever and fatigue. Risk factors include HIV/AIDS, chemotherapy and immunosuppressant drugs. Treatment includes an antimalarial drug and antibiotics.

### **REPORT HIGHLIGHTS**

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Toxoplasmosis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Toxoplasmosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Toxoplasmosis (Infectious Disease) pipeline guide also reviews of key players

involved in therapeutic development for Toxoplasmosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 1, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 2 molecules, respectively.

Toxoplasmosis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Toxoplasmosis (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Toxoplasmosis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Toxoplasmosis (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Toxoplasmosis (Infectious Disease) therapeutics

based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Toxoplasmosis (Infectious Disease)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Toxoplasmosis (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Toxoplasmosis (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



## Contents

Introduction

Global Markets Direct Report Coverage

Toxoplasmosis - Overview

Toxoplasmosis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Toxoplasmosis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Toxoplasmosis - Companies Involved in Therapeutics Development

AbbVie Inc

GSK plc

PGTx Ltd

Tiba Biotech LLC

Vaxinano SE

Toxoplasmosis - Drug Profiles

Monoclonal Antibodies for Ocular Toxoplasmosis - Drug Profile

Product Description

Mechanism Of Action

pyrimethamine - Drug Profile

Product Description

Mechanism Of Action

Recombinant Vector Vaccine for Protozoal Infection - Drug Profile

Product Description

Mechanism Of Action

Small Molecules for Toxoplasmosis - Drug Profile

Product Description

Mechanism Of Action

Small Molecules for Toxoplasmosis - Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit CDPK1 for Protozoal Infections - Drug Profile

Product Description

Mechanism Of Action

toxoplasmosis [type II delta KU80 RH strain] vaccine - Drug Profile

Product Description

Mechanism Of Action

toxoplasmosis vaccine - Drug Profile

Product Description

Mechanism Of Action

toxoplasmosis vaccine - Drug Profile

Product Description

Mechanism Of Action

Toxoplasmosis - Dormant Projects

Toxoplasmosis - Product Development Milestones

Featured News & Press Releases

Dec 07, 2021: FTC, States to recoup millions in relief for victims fleeced by 'Pharma Bro' scheme to illegally monopolize life-saving drug Daraprim

Apr 15, 2020: Oakrum Pharma announces the launch of Toxo Total Care patient services program to support Pyrimethamine 25mg tablets

Mar 31, 2020: Optime Care announces availability Of 25mg Pyrimethamine tablets for patients diagnosed with toxoplasmosis

Mar 11, 2020: Oakrum Pharma announces the launch of Pyrimethamine 25mg tablets in the United States

Feb 03, 2020: FDA grants approval of Daraprim drug's first generic to Cerovene

Jan 27, 2020: FTC and NY Attorney General charge Vyera Pharmaceuticals, Martin Shkreli, and other defendants with anticompetitive scheme to protect a list-price increase of more than 4,000 percent for life-saving drug Daraprim

Feb 03, 2016: Turing Pharmaceuticals Provides Key Facts to Congressional Oversight Committee

Jan 22, 2016: Turing Pharmaceuticals to Testify at Congressional Hearing on Drug Pricing

Dec 18, 2015: Continued Availability of Daraprim (pyrimethamine)

Nov 24, 2015: Texas Becomes Latest State ADAP to Add Daraprim (pyrimethamine) to Formulary

Oct 13, 2015: Turing Pharmaceuticals Announces Improvements in Daraprim Accessibility and Affordability

Sep 25, 2015: Keller Rohrback Investigates Turing Pharmaceuticals for Alleged Daraprim Price Gouging

Sep 24, 2015: Turing Pharmaceuticals Issues Statement on Daraprim Price Reduction

Sep 18, 2015: Turing Pharmaceuticals Provides Update On Availability Of Daraprim

Appendix  
Methodology  
Coverage  
Secondary Research  
Primary Research  
Expert Panel Validation  
Contact Us  
Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Toxoplasmosis, 2022  
Number of Products under Development by Companies, 2022  
Number of Products under Development by Universities/Institutes, 2022  
Products under Development by Companies, 2022  
Products under Development by Universities/Institutes, 2022  
Number of Products by Stage and Target, 2022  
Number of Products by Stage and Mechanism of Action, 2022  
Number of Products by Stage and Route of Administration, 2022  
Number of Products by Stage and Molecule Type, 2022  
Toxoplasmosis - Pipeline by AbbVie Inc, 2022  
Toxoplasmosis - Pipeline by GSK plc, 2022  
Toxoplasmosis - Pipeline by PGTx Ltd, 2022  
Toxoplasmosis - Pipeline by Tiba Biotech LLC, 2022  
Toxoplasmosis - Pipeline by Vaxinano SE, 2022  
Toxoplasmosis - Dormant Projects, 2022  
Toxoplasmosis - Dormant Projects, 2022 (Contd..1)



## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Toxoplasmosis, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

## I would like to order

Product name: Toxoplasmosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/T2510AD7A8F8EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/T2510AD7A8F8EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

